Megalin, a multi-ligand endocytic receptor, and its participation in renal function and diseases: A review

EGE Elsakka, MM Mokhtar, M Hegazy, A Ismail… - Life Sciences, 2022 - Elsevier
The endocytosis mechanism is a complicated system that is essential for cell signaling and
survival. Megalin, a membrane-associated endocytic receptor, and its related proteins such …

Albumin-based drug delivery: harnessing nature to cure disease

MT Larsen, M Kuhlmann, ML Hvam… - Molecular and cellular …, 2016 - Springer
The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic
levels, however, challenges such as rapid renal clearance, degradation or non-specific …

[HTML][HTML] Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease

R Nielsen, EI Christensen, H Birn - Kidney international, 2016 - Elsevier
Proximal tubule protein uptake is mediated by 2 receptors, megalin and cubilin. These
receptors rescue a variety of filtered ligands, including biomarkers, essential vitamins, and …

Estimation of health risks associated with dietary cadmium exposure

S Satarug, DA Vesey, GC Gobe, KR Phelps - Archives of Toxicology, 2023 - Springer
In much of the world, currently employed upper limits of tolerable intake and acceptable
excretion of cadmium (Cd)(ECd/Ecr) are 0.83 µg/kg body weight/day and 5.24 µg/g …

Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases

CP Argyropoulos, SS Chen, YH Ng… - Frontiers in …, 2017 - frontiersin.org
There is currently an unmet need for better biomarkers across the spectrum of renal
diseases. In this paper, we revisit the role of beta-2 microglobulin (β2M) as a biomarker in …

Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation

H Cho, SI Jeon, CH Ahn, MK Shim, K Kim - Pharmaceutics, 2022 - mdpi.com
Albumin has shown remarkable promise as a natural drug carrier by improving
pharmacokinetic (PK) profiles of anticancer drugs for tumor-targeted delivery. The …

Recent advances in nanotechnology-based drug delivery systems for the kidney

F Oroojalian, F Charbgoo, M Hashemi, A Amani… - Journal of controlled …, 2020 - Elsevier
The application of nanotechnology in medicine has the potential to make a great impact on
human health, ranging from prevention to diagnosis and treatment of disease. The kidneys …

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

S Glund, V Moschetti, S Norris… - Thrombosis and …, 2015 - thieme-connect.com
Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in
development as a specific antidote for dabigatran. In this first-in-human, single-rising-dose …

Diverse origins of the myofibroblast—implications for kidney fibrosis

LL Falke, S Gholizadeh, R Goldschmeding… - Nature Reviews …, 2015 - nature.com
Fibrosis is the common end point of chronic kidney disease. The persistent production of
inflammatory cytokines and growth factors leads to an ongoing process of extracellular …

Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?

AP Zavascki, RL Nation - Antimicrobial agents and chemotherapy, 2017 - Am Soc Microbiol
Nephrotoxicity is a common adverse effect of the clinically used polymyxins, colistin and
polymyxin B. This adverse effect is dose limiting for both polymyxins, as the plasma …